FGEN Fibrogen Inc

Price (delayed)

$19.98

Market cap

$1.88B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.14

Enterprise value

$1.87B

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue ...

Highlights
The net income is up by 19% since the previous quarter
The company's EPS rose by 19% QoQ
FGEN's gross profit is down by 46% year-on-year but it is up by 15% since the previous quarter
The company's revenue fell by 40% YoY but it rose by 15% QoQ
FGEN's equity has dropped by 182% since the previous quarter and by 110% year-on-year
The company's debt has surged by 50% QoQ and by 40% YoY

Key stats

What are the main financial stats of FGEN
Market
Shares outstanding
94.18M
Market cap
$1.88B
Enterprise value
$1.87B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
13.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.25
Earnings
Revenue
$140.73M
EBIT
-$291.86M
EBITDA
-$281.25M
Free cash flow
-$149.67M
Per share
EPS
-$3.14
Free cash flow per share
-$1.6
Book value per share
-$0.23
Revenue per share
$1.5
TBVPS
$6.52
Balance sheet
Total assets
$610.09M
Total liabilities
$611.57M
Debt
$139.22M
Equity
-$21.45M
Working capital
$219.26M
Liquidity
Debt to equity
-6.49
Current ratio
1.8
Quick ratio
1.6
Net debt/EBITDA
0.06
Margins
EBITDA margin
-199.8%
Gross margin
85.6%
Net margin
-208.7%
Operating margin
-213.9%
Efficiency
Return on assets
-44.3%
Return on equity
-440.4%
Return on invested capital
-84.1%
Return on capital employed
-86.7%
Return on sales
-207.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FGEN stock price

How has the Fibrogen stock price performed over time
Intraday
-0.1%
1 week
-0.15%
1 month
-16.09%
1 year
48.11%
YTD
24.72%
QTD
24.72%

Financial performance

How have Fibrogen's revenue and profit performed over time
Revenue
$140.73M
Gross profit
$120.45M
Operating income
-$301.03M
Net income
-$293.65M
Gross margin
85.6%
Net margin
-208.7%
Fibrogen's operating margin has plunged by 74% YoY but it has increased by 29% from the previous quarter
The company's net margin has shrunk by 69% YoY but it rose by 29% QoQ
FGEN's gross profit is down by 46% year-on-year but it is up by 15% since the previous quarter
The company's revenue fell by 40% YoY but it rose by 15% QoQ

Growth

What is Fibrogen's growth rate over time

Valuation

What is Fibrogen stock price valuation
P/E
N/A
P/B
N/A
P/S
13.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.25
The company's EPS rose by 19% QoQ
FGEN's equity has dropped by 182% since the previous quarter and by 110% year-on-year
The stock's price to sales (P/S) is 85% more than its last 4 quarters average of 7.2 but 22% less than its 5-year quarterly average of 17.1
The company's revenue fell by 40% YoY but it rose by 15% QoQ

Efficiency

How efficient is Fibrogen business performance
The company's return on sales has shrunk by 69% YoY but it rose by 29% QoQ
FGEN's return on equity has dropped by 51% since the previous quarter
FGEN's return on assets is down by 23% year-on-year but it is up by 14% since the previous quarter
FGEN's return on invested capital is up by 10% since the previous quarter but it is down by 9% year-on-year

Dividends

What is FGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FGEN.

Financial health

How did Fibrogen financials performed over time
FGEN's total assets is down by 21% year-on-year
FGEN's current ratio is down by 14% year-on-year and by 4.3% since the previous quarter
FGEN's equity has dropped by 182% since the previous quarter and by 110% year-on-year
The company's debt has surged by 50% QoQ and by 40% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.